Shandong Sinobioway Biomedicine Co Ltd (002581) — Strategic Asset Allocation Index
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Strategic Asset Allocation Index of 25.8% as of September 2023. Strategic assets (PP&E of CN¥650.15 Million plus long-term investments of CN¥-) total CN¥650.15 Million, measured against net assets of CN¥2.52 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Shandong Sinobioway Biomedicine Co Ltd (002581) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Shandong Sinobioway Biomedicine Co Ltd Strategic Asset Allocation Index (2007–2022)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of September 2023, the index stands at 25.8%, representing strategic assets of CN¥650.15 Million against net assets of CN¥2.52 Billion CNY. See 002581 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Shandong Sinobioway Biomedicine Co Ltd market cap and net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 28.6% | CN¥705.47 Million | CN¥705.47 Million | CN¥- | CN¥2.47 Billion | ▼ -0.3 pp |
| 2021 | 28.9% | CN¥713.76 Million | CN¥713.76 Million | CN¥- | CN¥2.47 Billion | ▼ -2.4 pp |
| 2020 | 31.3% | CN¥684.72 Million | CN¥684.72 Million | CN¥- | CN¥2.19 Billion | ▼ -1.4 pp |
| 2019 | 32.7% | CN¥780.90 Million | CN¥780.90 Million | CN¥- | CN¥2.39 Billion | ▼ -10.2 pp |
| 2018 | 42.9% | CN¥1.21 Billion | CN¥775.26 Million | CN¥434.74 Million | CN¥2.82 Billion | ▲ +10.1 pp |
| 2017 | 32.8% | CN¥958.15 Million | CN¥504.92 Million | CN¥453.22 Million | CN¥2.92 Billion | ▼ -0.2 pp |
| 2016 | 33.0% | CN¥835.20 Million | CN¥482.19 Million | CN¥353.01 Million | CN¥2.53 Billion | ▲ +0.9 pp |
| 2015 | 32.1% | CN¥688.46 Million | CN¥475.96 Million | CN¥212.50 Million | CN¥2.14 Billion | ▲ +10.5 pp |
| 2014 | 21.6% | CN¥162.14 Million | CN¥162.14 Million | CN¥- | CN¥749.40 Million | ▼ -4.8 pp |
| 2013 | 26.5% | CN¥195.54 Million | CN¥195.54 Million | CN¥- | CN¥738.31 Million | ▲ +4.1 pp |
| 2012 | 22.4% | CN¥157.95 Million | CN¥157.95 Million | CN¥- | CN¥704.41 Million | ▲ +6.6 pp |
| 2011 | 15.8% | CN¥106.08 Million | CN¥106.08 Million | CN¥- | CN¥672.28 Million | ▼ -32.0 pp |
| 2010 | 47.8% | CN¥84.78 Million | CN¥84.78 Million | CN¥- | CN¥177.34 Million | ▼ -1.4 pp |
| 2009 | 49.2% | CN¥63.79 Million | CN¥63.79 Million | CN¥- | CN¥129.71 Million | ▼ -6.3 pp |
| 2008 | 55.5% | CN¥64.42 Million | CN¥64.42 Million | CN¥- | CN¥116.12 Million | ▲ +10.7 pp |
| 2007 | 44.8% | CN¥37.59 Million | CN¥37.59 Million | CN¥- | CN¥83.94 Million | — |